Skip to content
My WebMD Sign In, Sign Up

Breast Cancer Health Center

Font Size
A
A
A

Femara Prevents Breast Cancer Recurrence

Drug Picks Up Where Tamoxifen Leaves Off in Reducing Cancer Risks

Questions Remain continued...

Experts say it's also too soon to say whether women should make an early switch from tamoxifen therapy to Femara before completing five years of treatment.

"For women generally doing well on tamoxifen, I think this study says to stay the course for five years and then think about switching," says Burstein, who also wrote an editorial that accompanies the study.

In fact, Burstein says this study suggests that the sequencing of using tamoxifen followed by an aromatase inhibitor might be important in order to achieve the most benefits but more studies are need to look at that issue further.

But for cancer survivor Cathy Anderson, who participated in the study and spoke at the briefing, this study has eased her mind.

"It's scary at the end of tamoxifen -- at the end of five years -- and knowing that you've got nothing to go on to," says Anderson, who took Femara during the study. "Personally, this means my risk recurrence has been cut in half. The results have provided women with hope."

1 | 2 | 3

Today on WebMD

Breast Cancer Health Check
HEALTH CHECK
breast cancer overview slideshow
SLIDESHOW
 
cancer fighting foods
SLIDESHOW
senior woman
Article
 
Breast Cancer Treatments Improving
VIDEO
Resolved To Quit Smoking
SLIDESHOW
 
Woman getting mammogram
Article
Screening Tests for Women
SLIDESHOW
 
ovarian cancer overview slideshow
SLIDESHOW
serious woman
Article
 
what is your cancer risk
HEALTH CHECK
10 Ways to Revitalize Slideshow
SLIDESHOW